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Abstract
Background: In healthy nonsmokers, inhaled endotoxin [lipopolysaccharide (LPS)] challenge induces airway
neutrophilia and modifies innate immune responses, but the effect on mucociliary clearance (MCC), a key host
defense response, is unknown. Although smokers are chronically exposed to LPS through inhaled tobacco
smoke, the acute effect of inhaled LPS on both MCC and airway inflammation is also unknown. The purpose of
this study was to determine the effect of inhaled LPS on MCC in nonsmokers and mild smokers with normal
pulmonary function.
Methods: We performed an open-label inhalational challenge with 20,000 endotoxin units in healthy adult
nonsmokers (n¼18) and young adult, mild smokers (n¼12). At 4 hr post LPS challenge, we measured MCC
over a period of 2 hr, followed by sputum induction to assess markers of airway inflammation.
Results: No significant changes in spirometry occurred in either group following LPS challenge. Following
LPS, MCC was significantly ( p < 0.05) slowed in nonsmokers, but not in smokers [MCC¼10 – 9% (challenge)
vs. 15 – 8% (baseline), MCC¼14 – 9% (challenge) vs. 16 – 10% (baseline), respectively]. Both groups showed a
significant ( p < 0.05) increase in sputum neutrophils 6 hr post LPS challenge versus baseline. Although there
was no correlation between the increased neutrophilia and depressed MCC post LPS in the nonsmokers,
baseline neutrophil concentration predicted the LPS-induced decrease in MCC in the nonsmokers, i.e., lower
baseline neutrophil concentration was associated with greater depression in MCC with LPS challenge
( p < 0.05).
Conclusions: These data show that a mild exposure to endotoxin acutely slows MCC in healthy nonsmokers.
MCC in mild smokers is unaffected by mild endotoxin challenge, likely due to preexisting effects of cigarette
smoke on their airway epithelium.
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Introduction
Endotoxin [lipopolysaccharide (LPS)], a major compo-nent of the outer membrane of gram-negative bacteria, is
a significant component of particulate pollutants in occupa-
tional settings and domestic environments,(1,2) having been
identified on both PM2.5 and PM10 particles(3,4) and ciga-
rette smoke.(5) We(6–8) and others (9–11) have shown that LPS
inhalation challenge, at levels [20,000 endotoxin units (EU)]
that induce airway neutrophilia but not decrements in lung
function or symptoms, causes depressed phagocytic host
defense function in nonsmoking, healthy adult volunteers.
Like phagocyte function, mucociliary clearance (MCC) is an
important primary host defense mechanism that protects the
lung(12) by clearing inhaled pathogens that might otherwise
persist and colonize in the airways. Although decreases in
MCC can be induced by inflammation,(12) it is unknown
whether MCC is affected by LPS-induced inflammation in
healthy nonsmokers.
Chronic smoking has been shown to slow MCC, espe-
cially in those with a long smoking history and with de-
velopment of chronic bronchitis.(13) Decreases in MCC can
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be induced by inflammation and almost certainly contribute
to mucus plugging and decreased clearance of inhaled irri-
tants and pathogens.(12) With increasing pack-year history,
smokers are also exposed to increasing levels of LPS
associated with cigarette smoke. We have shown that short-
term repeated challenge of LPS in healthy nonsmokers in-
duces tolerance to subsequent LPS-induced inflammation
and innate immune activation.(14) It is unknown, however,
whether smokers have acquired LPS tolerance from chronic
exposure to tobacco smoke and whether the MCC response
to LPS challenge is different from that of nonsmokers as a
result of their preexisting chronic LPS exposure. This study
examined the effect of inhaled LPS on in vivo MCC in
young, otherwise healthy adult mild smokers and non-
smokers.
We performed an open-label study comparing MCC and
regional particle deposition indices on a baseline study day
and after inhalational challenge with 20,000 EU of Clinical
Center Reference Endotoxin (CCRE) in young nonsmokers
and smokers with normal baseline lung function. Four hours
after inhaled endotoxin challenge, we assessed clearance of
inhaled, radiolabeled particles by gamma scintigraphy over
a 2-hr period. The 4-hr postchallenge time was chosen based
on our and others’ previous findings of increased inflam-
mation following LPS challenge measured by lavage or in-
duced sputum in the 3–6-hr postexposure time period.(6,15,16)
Following MCC measurements, we obtained induced spu-
tum samples for assessment of inflammatory cell counts,
i.e., neutrophils and macrophages. All endpoints were
compared with baseline measurements for each subject on a
nonchallenge, baseline study day.
Materials and Methods
Subjects
Eighteen (5 male/13 female) healthy nonasthmatic non-
smokers (age 19–48, mean 25) and 12 (8 male/4 female)
(age 21–45, mean 28) nonasthmatic mild smokers were
studied. Nonsmokers and smokers had normal baseline lung
function [FEV1 % pred ‡ 80, FEV1/FVC ratio ‡ 0.75 (FEV1,
forced expiratory volume in 1 sec; FVC, forced vital ca-
pacity)] and a negative methacholine challenge (less than a
20% decrease in FEV1 at a maximum methacholine con-
centration of 10 mg/mL).(17) Nonsmokers had negative al-
lergy skin tests, but smokers were only required to have no
current seasonal allergy symptoms (i.e., no skin tests). The
mean pack-years for these young, mild smokers was 6 – 3.5.
Informed written consent was obtained from all subjects
prior to their participation in the studies that were approved
by the Biomedical Institutional Review Board of the Uni-
versity of North Carolina at Chapel Hill. The studies were
listed on clinicaltrials.gov [NCT00839124 (nonsmokers)
and NCT00753870 (smokers)].
Study design
All subjects participated in a baseline and endotoxin
challenge study visit. During the subject’s baseline visit, we
measured, in order, spirometry, MCC of inhaled, radi-
olabeled particles by gamma scintigraphy(18–20) over a 2-hr
period, followed by sputum induction. The subject returned
the next day for a follow-up gamma camera scan (24-hr
retention). At least 3 days after the baseline visit, the subject
returned for the endotoxin challenge study visit. Spirometry
was measured before the endotoxin challenge. Postchallenge
monitoring included spirometry, vital signs, oxygen satura-
tion, and symptom score at the following intervals post
challenge: 30 and 60 min and then hourly for 3 additional
hours. At 4 hr post endotoxin challenge, we measured MCC
over a 2-hr period, immediately followed by induced spu-
tum. The subject returned the following day for the 24-hr
retention scan. Comparisons were made with MCC and in-
duced sputum endpoints obtained from the same subject
during the baseline visit.
Inhaled endotoxin challenge. CCRE was provided by the
National Institutes of Health Clinical Center; CCRE chal-
lenge will be referred to as LPS challenge. A dose of 20,000
EU was previously shown to induce sputum neutrophilia,
and was demonstrated to be safe and well tolerated in pre-
vious studies. Subjects inhaled the LPS solution (5 mL of
endotoxin solution in sterile water) via a DeVilbiss Ultraneb
99 ultrasonic nebulizer. While wearing noseclips, the sub-
ject was instructed to latch his/her mouth onto the nebulizer
mouthpiece and breathe normally (i.e., tidal breaths) until
the solution was spent (approximately 12–14 min).
Regional particle deposition and MCC. The procedure
we used for measuring and analyzing MCC in humans has
been described in detail previously.(18–20) A xenon (133Xe)
equilibrium lung scan was recorded for each subject on
their baseline visit to allow the creation of suitable regions
of interest (ROIs) for determining regional lung deposition
and MCC. For each measure of MCC, the subject inhaled
an aerosol (mass median aerodynamic diameter of 5 lm,
geometric standard deviation = 2.0) of sulfur colloid la-
beled with 99mTc (40 lCi; CIS-US, Inc., Bedford, MA)
from a DeVilbiss 646 nebulizer. While breathing the
radiolabeled aerosol, the subject matched his/her tidal flow
and breathing rate at 500 mL/sec and 30/min, respectively,
by following a visual flow signal while breathing in time to
a metronome. Immediately following inhalation of radio-
aerosol (duration of less than 2 min), an initial deposition
scan was recorded (sum of two 2-min images), and then
continuous 2-min images were recorded for a period of
2 hr to monitor clearance of particles from the lung as the
subject remained seated in front of the gamma camera. The
subject returned the following day after the radiolabeled
aerosol exposure to obtain a 30-min scan of 24-hr lung
activity/retention.
Only the right lung was used to analyze both regional
deposition and MCC because of the potential overlap of
stomach and lung activity on the left side. To assess central
(C) versus peripheral (P) deposition, two outline ROIs were
created over the right 133Xe lung image: (1) a rectangular
region around the entire right lung, and (2) a central ROI,
with dimensions equal to half the whole lung ROI’s width
and one-half its height. The central region was positioned on
the medial boundary of the lung, centered by height, 25% of
the area of the whole lung ROI. The peripheral region is the
area lying between the central and whole lung outline. These
regions were displayed over the initial aerosol scans to de-
termine the initial counts in each region. We then calculated
the ratio of central to peripheral counts, (C/P)Tc, and
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normalized this ratio by dividing by the central to peripheral
ratio for the 133Xe scan, (C/P)Xe:
(C=P)Tc=(C=P)Xe¼C=P: (1)
This normalization was done to account for the difference in
relative lung areas and thickness between the central and
peripheral regions. C/P provides an index of relative depo-
sition between the two regions. A C/P of 1.0 reflects equal
deposition in each region. However, because the central
region outlines both bronchial airways and lung parenchyma
surrounding these airways, a C/P of near unity reflects pri-
marily deposition in the pulmonary airspaces distal to ana-
tomic dead space. Increases in C/P to values greater than
unity reflect an increase in central versus peripheral depo-
sition primarily as a result of increased bronchial deposition.
Another measure of regional deposition heterogeneity is
the skew of the histogram distribution (counts/pixel versus
number of pixels)(21) within the right whole lung ROI, in-
creasing with increased frequency of ‘‘hot spots’’ in the
lung. These hot spots are presumed due to increased depo-
sition within bronchial airways throughout the lung so that
skew is independent of the specific region within the lung
(e.g., central versus peripheral). To determine skew, fre-
quency distribution histograms were constructed from the
right lung deposition images, with the number of pixels with
a given count value (expressed as a fraction of total pixels)
on the y axis and the count values on the x axis. These
histograms were analyzed for skew (a measure of histogram
symmetry, the third moment about the mean of the histo-
gram).(21) Heterogeneity of deposition increases with in-
creasing skew (i.e., more pixels with high counts/pixel).
The whole lung ROI bordering the right lung was used to
determine, by computer analysis, the whole lung retention
(Rt; decay and background corrected) as a fraction of the
initial counts in the right lung, over the 2-hr clearance period
at 10-min intervals (two 2-min images summed for each
10-min time point, e.g., images 1 and 2 for initial time 0 and
images 6 and 7 for time 10 min). Similarly, the 24-hr re-
tention (R24) was calculated. For each retention versus time
data set (e.g., mean data shown in figures), the average
clearance (MCC) [or 100 * (1- Rt)] over the 2-hr period
of observation (MCC) was computed (i.e., average of the
10-min clearance values from 10 to 120 min). The calcu-
lated MCC (in percent) represents the average clearance in
percent at the midpoint of our 10–120-min retention versus
time observations.(20)
Sputum induction and cell differentials
Sputum induction and processing were performed ac-
cording to previously published methods.(22,23) In brief,
subjects inhaled increasing concentrations (3%, 4%, and
5%) of hypertonic saline for 7 min each, for a total of
21 min. Manual selection of plug material was weighed and
treated with 0.1% dithiothreitol (DTT) for cell dispersion.
Differential cell counts were analyzed from Romanowski
(Diff-Quik)–stained slides, based on 400 cells, and ex-
pressed as a percentage of total nonsquamous nucleated
cells. Acceptable slides had a minimum of 50% viability
(trypan blue staining) and less than 20% squamous epithelial
cell content.
Statistical methods
Comparisons between baseline and postchallenge mea-
surements were analyzed using Student’s paired t test. The
significance of relationships between individual variables
was tested using nonparametric Spearman’s rank correlation
analysis (Stata for Macintosh). An overall significance level
of p £ 0.05 was considered to be significant. All values are
expressed as the mean ( – standard deviation). The number
of subjects to be studied was originally based on inflam-
matory endpoints, specifically changes in sputum neutro-
phils associated with a similar acute LPS challenge in
healthy nonsmokers.(22,23) But repeat measures of MCC in
healthy nonsmokers in our laboratory(20) also provided
paired standard deviation data that established some confi-
dence that we could detect a significant change in MCC
associated with the LPS challenge. Based on these data, an
Table 1. Summary of Lung Function (FEV1)

















102 (13) 100 (2) 101 (2) 100 (2)
Smokers 101 (12) 100 (2) 100 (4) 99 (4)
FIG. 1. (A) Whole lung MCC for baseline versus endo-
toxin challenge in healthy nonsmoker. (B) Whole lung MCC
for baseline versus endotoxin challenge in smokers.
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N of 15 would be required to observe a 50% change in
MCC for a two-sided paired analysis with a = 0.05 and
power = 0.80.
Results
Table 1 summarizes the baseline lung function (FEV1 %
pred) of the two cohorts and the postchallenge change be-
tween pre- and post-MCC measures, i.e., 3 and 6 hr post
challenge. There was no significant fall in FEV1 after LPS
challenge for either of the cohorts.
There was no difference in baseline MCC or regional
deposition between the nonsmokers and smokers. In healthy
nonsmoking subjects, whole lung MCC was significantly
decreased after inhaled LPS challenge compared with
baseline conditions (Fig. 1A and Table 2). There was no
baseline versus challenge difference in regional deposition
(C/P, skew, or %24hr) for the initial scan after radiolabeled
aerosol inhalation (Table 1). For the smokers, there was no
difference in whole lung MCC between LPS challenge and
baseline study days (Fig. 1B and Table 2). There was also no
difference in regional deposition for baseline versus chal-
lenge in the smokers.
Table 3 summarizes the results for inflammatory cell
differentials obtained by sputum induction on the baseline
and LPS challenge days. Only neutrophils and macrophages
are shown, as they are the predominant cell types recovered
from sputum. Both groups showed a significant increase in
neutrophil concentrations following LPS exposure, whereas
the macrophage concentrations showed no change (except
as a reduced percentage of the total due to the increased
percentage of neutrophils). There was a trend, although not
significant, for the nonsmokers to have higher baseline neu-
trophil concentrations compared with the smokers. There were
no significant correlations between the increase in inflamma-
tory cells and the changes in MCC seen in the nonsmokers.
However, there was a statistically significant association be-
tween baseline neutrophils (as percent total cells) and the rel-
ative decrease in MCC among the nonsmokers ( p = 0.026, and
R = 0.52 by Spearman rank correlation), i.e., the lower the
baseline sputum neutrophils, the greater the relative decrease in
MCC compared with baseline.
Discussion
To our knowledge, this is the first study to use an LPS
inhalation challenge protocol at a concentration known to
induce airway inflammation in order to assess the effect of
LPS on MCC (an important host defense mechanism to
protect the airways from inhaled toxins and bacteria) in
normal volunteers and mild smokers. The LPS challenge in
this study approximates levels encountered in domestic and
low-level occupational exposures, yet does not cause in-
creased symptoms or overt changes in spirometric measures.
We again found no effect on lung function for either of these
groups (Table 1). However, we now report for the first time
a slowing of MCC in healthy nonsmoking adults, with no
effect of LPS on MCC in mild smokers.
Contrary to what we observed in nonsmokers, we found that
mild smokers were resistant to the effect of LPS on MCC.
Although our study was not designed to assess molecular
mechanisms of response to LPS in these populations, we hy-
pothesize that smokers may have acquired tachyphylaxis or
tolerance to inhaled LPS from chronic exposure to tobacco
smoke. In vitro studies of inflammatory cells have demon-
strated that repeated exposure to LPS may result in tolerance to
subsequent doses of LPS.(24) Such tolerance may also apply to
the epithelial cells that comprise the MCC apparatus. We have
recently reported that repeated short-term nasal challenge with
LPS blunted inflammation (neutrophils) and decreased LPS-
related innate immune responses (sCD14) when compared
with a single LPS challenge in healthy volunteers.(14) Tobacco
smoke is a rich source of LPS,(5) suggesting that smokers have
chronic exposure to inhaled LPS. Alveolar macrophages from
smokers have been found to have decreased inflammatory
response to toll-like receptor 2 (TLR2) and TLR4 ligands, and
smoking has been shown to decrease the antibacterial and
phagocytic activities of macrophages,(25,26) suggesting that
these cells from smokers have decreased LPS responsive-
ness.(27) Tobacco smoke preparations have been shown to
modulate TLR-mediated responses in epithelial cells, although
Table 2. Mean (SD) of MCC and Regional
Deposition Indices for Each Cohort on Baseline
and LPS Challenge Study Days
Whole-lung
MCC (%) C/P Skew %24hr
Healthy nonsmokers
Baseline 15 (8) 1.88 (0.39) 1.83 (0.57) 49 (14)
LPS
challenge
10 (9)a 1.90 (0.51) 1.90 (0.55) 48 (14)
Smokers
Baseline 16 (10) 1.75 (0.58) 1.94 (1.12) 44 (14)
LPS
challenge
14 (9) 1.76 (0.63) 1.75 (1.01) 43 (15)
ap < 0.05 compared with baseline by paired Student’s t test.
Table 3. Mean (SD) Cell Counts From Induced Sputum (% and Cells/Mg in Sample)
PMNs (as % (SD) and cells/mg (SD)) Macrophages (as % (SD) and cells/mg (SD))
Base LPS Base LPS
Nonsmokers (n = 18) 44.1 (27.4) 65.9 (22.1)a 53.6 (27) 32.5 (22)a
925 (955) 2,706 (2958)a 902 (665) 945 (799)
Smokers (n = 12) 50 (17) 71 (11.3)a 46.9 (16.3) 23.6 (7.7)a
499 (527) 1,410 (1237)a 453 (433)b 472 (401)
PMN, polymorphonuclear neutrophils.
ap < 0.05 compared with baseline by paired Student’s t test.
bp < 0.05 compared with nonsmokers’ baseline by Student’s t test.
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the effect of chronic smoking on epithelial cell mucin response
to LPS is under-studied. However, these observations suggest
that decreased inflammatory and epithelial cell response to
endotoxin may account for the lack of effect of LPS on MCC
we observed in the smokers.
Little is known regarding the acute effects of LPS on the
various components of the mucociliary apparatus, namely,
mucus secretion, epithelial cell responses, and ciliary
function that might explain the slowing of MCC we ob-
served in the healthy nonsmokers. Chronic LPS exposure
stimulates production and expression of MUC5AC in animal
and in vitro models.(28,29) MUC5AC is considered to be the
most important mucin in the pathogenesis of mucus hyper-
secretion.(30) Moreover, this effect appears to be associated
with inflammation, because dexamethasone, a corticoste-
roid, was shown to inhibit chronic LPS-induced increased
MUC5AC expression in a rat study.(28) These authors also
demonstrated that TLR4, found on airway epithelial and
inflammatory cells, was associated with the LPS-stimulated
mucus hypersecretion. However, whether a single dose of
LPS in vivo acutely influences airway mucin secretions and
TLR4 expression on epithelial cells is not known. On the
other hand, if acute exposure to LPS acts as an irritant
mucus secretagogue, MCC might acutely increase in both
groups, i.e., immediately after exposure, such that after 4 hr,
airway mucus might be depleted and MCC would exhibit
slowing, as we observed in the nonsmokers. This phenom-
enon might be less apparent in smokers if they have a
greater mucus-secreting capacity due to chronic exposure to
irritants. In fact, the smokers may be tolerant because they
can secrete more mucus, in effect maintaining a continuous
mucus blanket on the airway surface over the 4-hr time
period post LPS.
With regard to cilia effects, Wyatt et al.(31) exposed cil-
iated bovine bronchial epithelial cell cultures to hog barn-
dust extract and found that ciliary beat frequency (CBF) was
enhanced, but they also showed that LPS was not respon-
sible for the increase. When LPS was added directly to the
ciliated cells, there was no change in CBF. A series of
earlier in vivo studies from Ohashi et al.(32–34) showed cil-
iary dysfunction of the middle ear and eustachian tube as-
sociated with LPS exposure in a dose-dependent fashion.
Exposures to the middle ear led to otitis media with effusion
in their animal model.(33,34) The mechanism of action for
LPS depression of cilia function is not clear, however, from
these studies.
The presence of high numbers of neutrophils seemed to be
protective to slowing of MCC by LPS challenge within the
nonsmokers, as evidenced by the significant correlation be-
tween baseline neutrophilia and the change in MCC in these
individuals. It has been shown that polymorphonuclear neu-
trophils may release ATP in response to various stimuli,(35)
and smokers have been shown to have elevated ATP in
lavage compared with nonsmokers.(36) ATP in turn is known
to enhance MCC by increasing ciliary and secretory activ-
ity.(37) This mechanism may offset the LPS-induced de-
pression on the MCC apparatus.
Our young, mild smokers did not appear to differ in
baseline MCC from the healthy nonsmokers. Given the low
pack-years for our smokers and their lack of lung function
impairment, such a result is not surprising and is consistent
with previous findings.(12,13) What differentiates the mild
smokers from the healthy nonsmokers is more likely how
the MCC apparatus responds to various stimuli as we have
shown here with the acute effect of endotoxin. We also
studied fewer smokers than nonsmokers, although we think
that unlikely to have affected either the difference in MCC
(Table 2) between the two groups ( p = 0.81 for group
comparison) or the lack of effect of LPS on MCC in
smokers. With regard to the latter, an estimated N = 77
would have been required to detect the absolute LPS-
induced reduction of MCC = 2.1 – 7.4% in the smokers with
a power of 0.80 and one-sided a = 0.05.
Finally, as suggested above, the time profile of the MCC
response post LPS challenge in either of our study groups
may be quite different from that of the inflammatory re-
sponse. The assessment of sputum and blood inflammatory
endpoints at 3–6 hr post LPS has been supported by a
number of investigators and studies.(17) These studies show
that, following inhaled LPS exposure, there is a rapid influx
of blood neutrophils into the airways as a result of the
production of chemotactic factors from activated airway
macrophages. This takes place in the lung wall very shortly
after exposure and peaks a few hours thereafter.(16) In our
own specific case, we have been interested in comparing the
response of LPS with that of ozone.(23) Early studies with
ozone challenge clearly showed that airway inflammation
compared at 1, 6, and 24 hr post exposure was greatest at the
6-hr time point.(38) More recent studies with LPS challenge
have shown a similar time course for LPS-induced inflam-
mation.(39,40) As discussed above, the acute response (im-
mediately post LPS challenge) of MCC in either study group
may have been quite different from what we observed at
4 hr. Nevertheless, in this initial study on the effects of LPS
exposure on MCC, we wanted to maintain similar timing to
our previous studies so that we could compare the MCC and
inflammatory responses at or near the same time post
challenge. Future studies should assess the time course of
the change in MCC post LPS exposure to better understand
the mechanisms by which LPS affects MCC.
Conclusion
In conclusion, we have found that an acute inhalation of
LPS significantly slows whole lung MCC and increases
airway neutrophils in healthy nonsmokers. The mild
smokers, on the other hand, showed no effects of LPS
challenge on MCC despite also showing increased neu-
trophilia, likely due to established tolerance from chronic
LPS exposure associated with inhalation of cigarette smoke.
The slowing of MCC by LPS may further enhance the
toxicity of other inhaled particulate matter by increasing
their residence time in the bronchial airways.
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